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Single Center Experience of Five Diffuse Panbronchiolitis 
Patients Clinically Presenting as Severe Asthma
Diffuse panbronchiolitis (DPB) is a bronchiolitis affecting the whole lung fields which can 
be treated by macrolide. Especially East Asian patients are more susceptible to diffuse 
panbronchiolitis. As asthma and DPB both can cause airway obstruction, differential 
diagnosis is important for the 2 diseases. Here we report 5 patients with DPB clinically 
presenting as severe asthma in Korea, who were well treated by macrolide. Among the 5 
patients, 2 could stop their asthma inhalers and the other 3 could reduce asthma 
medications after diagnosis and treatment of DPB. In conclusion, considering DPB as 
differential diagnosis for asthmatics in Asian ethnic groups is important.
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INTRODUCTION
Asthma is an obstructive lung disease diagnosed by variable 
airway obstruction. However, before diagnosis, other underly-
ing causes should be excluded (1). One of them is diffuse pan-
bronchiolitis (DPB) which incidence is high among Asians, es-
pecially Koreans and Japanese (2). Clinical manifestations of 
DPB are cough, dyspnea, and crackling sounds. A chest image 
shows bilateral centrilobular nodules. Although DPB is distinct 
from asthma, their clinical manifestations can overlap (3) and 
co-occurrence of DPB and asthma is possible in East Asian pa-
tients (4).
 DPB can be treated successfully with long-term, low-dose 
macrolide administration. The effectiveness of macrolide has 
been confirmed in a double-blind, placebo-controlled study 
(5). Macrolide is an antimicrobial and anti-inflammatory agent 
(6). Macrolide can alter neutrophil functions, inhibit oxidant 
production, and influence the production of various cytokines 
and chemokines, such as interleukin (IL)-1, IL-6, IL-8, IL-10, 
and tumor necrosis factor (7). In this report, we describe 5 Ko-
rean patients with DPB who clinically presented with severe 
asthma but for whom computed tomography (CT) findings were 
suggestive of DPB; these patients showed a good response to 
long-term macrolide treatment. 
CASE DESCRIPTION
Case 1
A 71-yr-old woman referred for a 10-yr history of cough, dys-
pnea, sputum, post-nasal drip on 4th June 2010. Her breathing 
sound was clear. A chest x-ray (CXR) showed increased bron-
chovascular markings in the both lower lungs and consolida-
tion in the left lower lung field (LLLF) (Fig. 1A). Initial forced 
expiratory volume in 1 second (FEV1) was 1.21 L (64.9%) and 
forced vital capacity (FVC) was 1.70 L (75.5%) and FEV1/FVC 
was 71.1% without a bronchodilator (BD) response. The metha-
choline bronchial provocation test (MBPT) was positive as a re-
sult of provocative concentration (PC20) was 3.8 mg/mL. Induc-
ed sputum showed mild eosinophilia (3%). During one month 
of asthma treatment with inhaled budesonide combined with 
formoterol, theophylline, and montelukast, she complained of 
mild fever and yellowish sputum. Thus, we performed a chest 
CT and water’s view x-ray. Bilateral maxillary sinusitis was ob-
served (Fig. 1B). CT showed bronchial wall thickening with cen-
trilobular nodules, which was suggestive of DPB (Fig. 1C, D). To 
differentiate from mycobacterial infection (8), acid fast bacilli 
(AFB) studies were done and showed negative. The patient took 
clarithromycin 250 mg twice a day for 9 months, after which her 
FEV1 improved from 64.9% to 84.2%, FVC and FEV1/FVC also 
improved. A follow-up examination, LLLF consolidation and 
sputum eosinophilia disappeared. In addition, she was able to 
reduce the daily amount of inhaled steroid and discontinue 
theophylline. 
Case 2
A 52-yr old man visited for a 4-yr history of cough, dyspnea, snee-
zing, rhinorrhea, and wheezing on 25th June 2010. Initial FEV1 
was 1.74 L (54.4%), FVC was 2.40 L (61.3%), and FEV1/FVC was 
72.5%. BD response was positive (FEV1 increased 20.6%, 270 
mL). CXR showed multiple nodules in both lungs. A sinus CT 
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showed bilateral maxillary sinusitis. A chest CT showed a tree-
in-bud appearance and air trapping in both lower lungs. Induc-
ed sputum showed neutrophilia. He showed a poor response to 
inhaled budesonide combined with formoterol and montelu-
kast. As AFB studies were negative, we administered clarithro-
mycin. The patient took clarithromycin 250 mg twice a day for 9 
months, after which FEV1 improved from 54.4% to 95.3%, FVC 
improved from 61.3% to 92.8%, and FEV1/FVC also improved. 
Cough and sputum disappeared. He now takes montelukast 
and clarithromycin without respiratory symptoms.
Case 3
A 25-yr-old man had a 5-yr history of cough and dyspnea on 
28th March 2007. Initial FEV1 was 2.51 L (62.6%), FVC was 3.65 
L (77.8%), and FEV1/FVC was 68.8%. BD response was negative. 
The results of a MBPT were positive (PC20 4.36 mg/mL). A CXR 
showed miliary nodules in both lungs, but he didn’t have sinus-
itis. A chest CT showed bronchiolectasis and centrilobular nod-
ules on both lungs (Fig. 2A, B). Induced sputum showed severe 
eosinophilia (42%). The AFB studies were negative. He took in-
haled fluticasone combined with salmeterol, montelukast, and 
theophylline, and he intermittently used 30 mg of prednisolone 
Fig. 1Fig. 1Fig. 1
A
C
B
D
Fig. 1. Images of the Case 1. Initial chest x-ray showed bilateral haziness at bilateral lung field (A) and both maxillary sinusitis (B). Chest CT showed diffuse bronchial wall thick-
ening with centrilobular nodules (C, D).
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(PL) for asthma attacks. After the patient took clarithromycin 
250 mg twice a day for 9 months, his FEV1 improved from 62.6% 
to 88.4%, and he could reduce the amount of PL. Before the pa-
tient had started taking clarithromycin, he had taken 720 mg of 
PL per year. After he treated with clarithromycin, he was able to 
reduce use of oral steroids by about 80%, such that he took 150 
mg per year.
Case 4
A 60-yr-old woman referred for a 5-yr history of severe asthma 
on 18th August 2010. Cough and dyspnea were her main symp-
toms. Her initial FEV1 was 0.88 L (42.9%), FVC was 1.10 L (44.9%), 
and FEV1/FVC was 73.4% without a BD response. A crackling 
sound was heard in both lungs. A chest CT showed diffuse bron-
chial wall thickening and centrilobular nodules with a tree-in-
bud appearance in both lower lungs (Fig. 3A, B). Induced spu-
tum showed 2% eosinophils. A MBPT could not be performed. 
Water’s view showed bilateral maxillary sinusitis. She had been 
using inhaled budesonide combined with formoterol, a tiotro-
pium inhaler, montelukast, and theophylline for a month. After 
a month, she complained of continuous cough and sputum. 
The crackling sound was consistently heard. The AFB studies 
were negative, and clarithromycin was introduced. The patient 
took clarithromycin 250 mg twice a day for 5.5 months with as-
thma medication, after which her FEV1 improved from 0.88 L 
(42.9%) to 1.96 L (97.1%), and FVC improved from 44.9% to 98.8%. 
Follow-up chest CT after a year showed improved centrilobular 
nodules in both lungs. She was able to discontinue budesonide 
and formoterol.
Case 5
A 69-yr-old man came with a 3-yr history of cough, sputum, and 
dyspnea on 11th July 2012. His initial FEV1 was 1.88 L (79.2%), 
FVC was 2.34 L (76.8%), and FEV1/FVC ratio was 80.3%. FEV1 
increased 13.2% (250 mL) after bronchodilator inhalation. In-
duced sputum showed neutrophilia without eosinophils. CXR 
showed tiny nodules and bronchial wall thickening in both low-
er lungs (Fig. 4A). Water’s view showed left maxillary sinusitis 
Fig. 2Fig. 2
A B
Fig. 2. Images of the Case 3. Bronchiolectasis and centrilobular nodules were observed on almost entire lung in his chest CT (A, B).
Fig. 3Fig. 3
A B
Fig. 3. Images of the Case 4. Initial CT showed bronchial wall thickening, centrilobular nodules (A, B).
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Fig. 4. Images of the Case 5. Tiny nodules, bronchial wall thickening (A) and left maxillary sinusitis (B) were observed. Initial CT showed severe and diffuse centrilobular nodules 
(C). After treatment, multiple nodules were decreased (D).
(Fig. 4B). A chest CT showed severe and diffuse centrilobular 
nodules and branching linear opacities in both lungs (Fig. 4C). 
The AFB studies were negative. He was prescribed fluticasone 
combined with salmeterol, pranlukast, myrtol, and clarithro-
mycin. After the patient took clarithromycin 250 mg twice a day 
for 40 days, his cough and sputum decreased. A follow-up CT 
showed a slight decrease in bronchial wall thickening and mul-
tiple nodules throughout both lungs (Fig. 4D). After 8 months 
of clarithromycin, he was able to use only fluticasone and sal-
meterol inhaler with clarithromycin. His FEV1 increased from 
79.2% to 127.0%, and FVC increased from 76.8% to 118.9%.
 The study occurred in the allergy clinic of a tertiary teaching 
hospital in Korea. We collected 5 patients who visited as severe 
asthma but treated well with DPB treatment. Institutional re-
view board reviewed and approved this study (4-2014-0362). 
DISCUSSION
All patients in this study were referred to our clinic with treat-
ment resistant severe asthma, but our report shows that DPB 
should be excluded before diagnosing asthma in East Asian pa-
tients. As DPB is a progressive inflammatory airway disease and 
can be treated by long-term administration of macrolide (9), ac-
curate diagnosis is especially important. Both asthma and DPB 
patients complain of chronic cough, sputum, and dyspnea, and 
it is not easy to discriminate between the two diseases. All 5 pa-
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tients had CT findings that were consistent with DPB, and all 
showed marked improvement in lung function and clinical sym-
ptoms with long-term macrolide treatment.
 In this study, all patients were treated with clarithromycin, 
which consists of 14-membered ring macrolides. The mecha-
nism by which macrolides manage DPB may be related to their 
immune modifying effects. Only 14-membered ring macrolides 
(erythromycin, clarithromycin, and roxithromycin) and 15-mem-
bered ring macrolides (azithromycin) are effective; 16-mem-
bered ring macrolides are not effective. The structure of macro-
lides determines their immune modifying activity (10), and it 
has been reported that macrolides could reduce airway mucus 
secretion and decrease airway neutrophil accumulation through 
reduced expression of adhesion molecules or cytokine expres-
sion from macrophages, lymphocytes, monocytes, fibroblasts, 
and eosinophils (10). The treatment effects of macrolides in DPB 
have been reported independent of the presence or absence of 
Pseudomonas infection, and the treatment effect can be observ-
ed below the minimum inhibitory concentration of macrolides, 
(10, 11) suggesting that immune modifying effects of macrolides 
are crucial for management of DPB. 
 Previously, the lower airway has been regarded as a bacteria-
free area, but recent data show that bacterial colonization can 
occur in asthma (12, 13) and chronic obstructive pulmonary 
disease (COPD) (14). These bacteria may exacerbate chronic 
airway diseases (14). In addition to their immune-modifying 
effects, macrolides have anti-microbial properties that may play 
a role in the management of other chronic airway diseases, such 
as asthma, COPD (15), cystic fibrosis, and chronic rhinosinus-
itis (16). For cystic fibrosis patients on long-term macrolide treat-
ment, the prevalence of sputum culture positivity for Haemoph-
ilus influenzae and Streptococcus pneumoniae are markedly de-
creased, although positive rates of these bacteria with macro-
lide resistance are much higher (17, 18). Decreased bacterial 
burden may contribute to the effect of long-term treatment of 
macrolides. Emergence of macrolide-resistant bacteria is an 
important concern related to the long-term administration of 
macrolides, but no cases have been reported in which macro-
lide-resistant bacterial infection led to a life threatening episode 
(2). In conclusion, it is essential to consider DPB for treatment 
resistant asthmatics in East Asian patients. DPB can be treated 
well by long term use of clarithromycin. 
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